New Blood Getting into Medical Sales

Twenty years ago few people perceived pharmaceutical sales as a career choice - it was something they fell into usually through the recommendation of...

Preparing for Appraisal

Most pharmaceutical companies now have a very robust appraisal system which measures not only your sales/activity performance but also your skills set. This should...

12 Types of Sales Call Reluctance

In the previous four articles we dealt with the causes of sales call reluctance and how it can dramatically affect the productivity of sales...

The Ultimate Guide To Interview Questions

    Not all interviews are the same, but...

The Customer is Always Right

DEALING WITH DIFFICULT CUSTOMERS As you’ve probably discovered, the old adage “the customer is always right” isn’t always t...

Creating Habits For SUCCESS

  We first make our habits and then our habits make us When you think now about the word...

Under Pressure

     With the economy taking a downward spiral in recent months, it is important for companies to be prepared to...

Going the extra mile

I am sure that we all have our ideas of what constitutes good customer service, after all most...

So Why Do You Want This Job

  Whether you are an old hat at interviews or this is your first time, it can still be a...

Have You Lost It?

  What happens when you are used to being “Number One”, the best sales person in your team and then...

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...